Shanghai's EpimAb Closes $25 Million A Round for Bi-Specifics

EpimAb Biotherapeutics, a Shanghai bispecific antibody company, closed a $25 million Series A round, led by Suzhou's Oriza Seed Capital. Founded in 2015, EpimAb developed its novel FIT-Ig® (Fabs-In-Tandem Immunoglobulin) platform, which generates bispecific molecules with antibody-like properties. EpimAb believes its molecules will prove to be more potent, less immunogenic and easier to manufacture than the competition. EpimAb, which is building a pipeline of immuno-oncology candidates, expects to start its first clinical trial in 2018. More details.... Share this with colleagues: // //